Magnesium aspartate oral
- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Oral formulations of magnesium aspartate.
1 to 2 sachets daily (243mg to 486mg magnesium or 10mmol to 20mmol magnesium).
Children aged 10 to 18 years
1 sachet daily (243mg magnesium or 10mmol magnesium).
Children aged 4 to 10 years
One level 5ml spoon daily (109mg magnesium or 4.5mmol magnesium) or 1 sachet daily (243mg magnesium or 10mmol magnesium).
Children aged 2 to 4 years
One level 5ml spoon daily (109mg magnesium or 4.5mmol magnesium).
Children aged under 2 years
Can be dissolved in 50ml to 200 ml water, tea or orange juice. Stir until the solution in water is cloudy to transparent. In orange juice or tea inactive particles will be visible. The solution should be taken immediately following reconstitution or within 24 hours when dissolved in bottled water and stored below 25 degrees celsius.
If necessary, magnesium aspartate dissolved in 200ml water can be administered via a gastric, duodenal, and nasal feeding tube. This should be administered immediately following reconstitution or within 24 hours when dissolved in bottled water and stored below 25 degrees celsius.
Children under 2 years
Hereditary fructose intolerance
Renal impairment - creatinine clearance below 30 ml/minute
Precautions and Warnings
Glucose-galactose malabsorption syndrome
Preparation contains sucrose
Monitor serum electrolytes
Interrupt or reduce dose if diarrhoea occurs
Prolonged treatment may lead to dental caries
Pregnancy and Lactation
Magnesium aspartate can be used during pregnancy if clinically needed.
Data from more than 1000 pregnancy outcomes indicate no malformative nor feto/neonatal toxicity of magnesium.
The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Magnesium aspartate can be used during breastfeeding.
Magnesium aspartate and it's metabolites are excreted in human milk, but at therapeutic doses, no effects on the breastfed newborn or infant are anticipated.
Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
Specialist advice is available from the UK Drugs in Lactation Advisory Service at https://www.midlandsmedicines.nhs.uk/content.asp?section=6&subsection=17&pageIdx=1
Can be dissolved in 50ml to 200 ml water, tea or orange juice. Stir until the solution in water is cloudy to transparent. In orange juice or tea inactive particles will be visible. The solution should be taken immediately after being prepared.
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: November 2018.
Summary of Product Characteristics: Magnaspartate 243mg Powder for Oral Solution. Kora Healthcare Ltd. Revised July 2020.
NICE Evidence Services Available at: www.nice.org.uk Last accessed: 14 November 2018
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.